BPGC

BPGbio is a clinical-stage biotechnology company that leverages its proprietary Interrogative Biology platform to redefine drug discovery and development. By combining AI-driven data analysis with a deep focus on human biology and multi-omics, the company identifies novel biomarkers and therapeutic targets across oncology, neurology, and rare diseases. Their lead candidate, BPM31510, is a small molecule metabolic modulator currently being evaluated in clinical trials for aggressive cancers like glioblastoma and pancreatic cancer. BPGbio aims to reduce the time and cost of drug development while increasing the probability of clinical success through its data-centric approach.